Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study

作者：Dongming Zhang, Xiaoyan Liu, Fangfang Shen, Dahai Zhao, Yuequan Shi, Haoran Zhang, Jia Liu, Xiaoxing Gao, Minjiang Chen, Jing Zhao, Wei Zhong, Junzhen Gao, Min He, Yonggang Liu, Xiaoling Yang, Jianwen Qin, Yuling Tang, Xinlin Mu, Yangchun Gu, Shucai Zhang, Xueqin Chen, Li Pang, Qingwei Meng, Ye Guo, Yuhui Zhang, Wěi Li, Puyuan Xing, Yuan Cheng, Tao Xin, Qingxia Li, Yu Hong Li, Jun Chen, Feng Gao, Bo Jin, Antônio Rossi, Hiroyuki Adachi, Francesco Guerrera, Hatim Husain, Yan Xu, Mengzhao Wang · 发表于：Translational Lung Cancer Research · 年份：2023 · DOI：10.21037/tlcr-23-577 · 被引用次数：20 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Melanoma and MAPK Pathways

Correspondence to: Yan Xu, MD, PhD; Mengzhao Wang, MD, PhD. Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan Wangfujing Dongcheng District, Beijing 100730, China. Email: maraxu@163.com; mengzhaowang@sina.com. Background: In the phase 3 FLAURA trial, osimertinib was compared with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib showed longer progression-free survival (PFS), overall survival (OS), and a similar safety profile. However, more studies demonstrating the effectiveness and safety of osimertinib as a first-line strategy are needed in real-world populations. Methods: We enrolled 1,556 patients with EGFR-mutated stage IIIc–IV NSCLC from the CAPTRA-Lung database. All patients received either osimertinib (n=202) or a first-generation EGFR-TKI (n=1,354) as their initial treatment. To adjust for differences in baseline characteristics between two groups, 1:2 propensity score matching (PSM) was performed. Propensity scores included gender, age, Eastern Cooperative Oncology Group performance status score, smoking history, family history of tumor, pathology, EGFR mutations, and central nervous system (CNS) metastases. The standardized mean differences (SMD) before and after PSM were calculated to examine the balance of co...